In the same announcement, Coherus reported that in the process of inspecting three sites in China enrolling patients for two pivotal trials of its PD-1 antibody toripalimab in recurrent nasopharyngeal carcinoma (NPC), the FDA identified one observation
Soc 81, 162167
Cell Host Microbe 10 , 248259 (2011)
And growing evidence of its anti-inflammation properties, notes Scripps computational biologist and study co-principal investigator Julia Vogel, has driven increasing interest in using GLP-1 drugs to treat at least some of long COVIDs myriad symptoms, which range from brain fog and difficulty breathing to fatigue and joint pain
The regulatory gray zone that sustained much of the compounding industry through 2023 and 2024 has narrowed substantially, and the FDA is actively working to close it
Cagrilintide cant be codissolved with semaglutide so NVO will commercialize CagriSema in a dual-chamber injection device and thus sales potential is TBD, according to the Leerink note